This article summarizes the published data on final height after growth-promoting therapy in Turner syndrome. Using growth hormone (GH) doses ranging between 0.5 and 1.2 IU/kg/week, final height after therapy is improved by 1.5–9.3 cm [final height after therapy vs. projected adult height (PAH)] within various studies. There is no obvious GH dose-response relationship, but a better estimated benefit from therapy seems to result in those studies that combined even rather low GH doses with the anabolic steroid oxandrolone. It is not possible to retrospectively define an optimal treatment regime out of the various published data due to different GH doses, age and dosage of estrogen replacement therapy and the variable methods for calculating the benefit from therapy. It seems to be essential to start estrogens at a safe bone age (> 13 years) in very low doses. Higher GH doses (up to 2.0 IU/kg/week) led to a better growth response during the first years of therapy but data on final height are still to be awaited.

Keywords:
Turner syndrome, Growth hormone, Final height
1.
Rosenfeld RG, Rodriguez RL, McCauley E, Albertsson-Wikland K, Cara J, Conte F, Hall JG, Lippe B, Nagel T, Neely E, Page D, Ranke M, Saenger P, Watkins J, Wilson DM: Recommendations for diagnosis, treatment, and management of individuals with Turner Syndrome. Endocrinologist 1994;5:351–358.
2.
Saenger P: Turner syndrome. N Engl J Med 1996;335:1749–1754.
3.
Hintz RL: Current and potential therapeutic uses of growth hormone and insulin-like growth factor I. Endocrinol Metab Clin North Am 1996;25:759–773.
4.
Ranke MB: Growth hormone therapy in Turner syndrome. Horm Res 1995;44(suppl 3):35–41.
5.
Rosenfeld RG, Hintz RL, Johanson AJ: Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial. J Pediatr 1986;109:936–943.
6.
Rudmann D, Goldsmith M, Kutner M, Blackston D: Effect of growth hormone and oxandrolone singly and together on growth rate in girls with X chromosome abnormalities. J Pediatr 1980;96:132–135.
7.
Werther GA, Dietsch S, for the Australasian Paediatric Endocrine Group: Multicenter trial of synthetic growth hormone and low dose oestrogen in Turner syndrome: Analysis of final height; in Albertsson-Wikland K, Ranke M (eds): Turner Syndrome in a Life Span Perspective: Research and Clinical Aspects. Amsterdam, Elsevier, 1995, pp 105–112.
8.
Rosenfeld RG, Frane J, Attie KM, Brasel JA, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J, Lippe BM, Mahohney PC, Moore WV, Saenger P, Johanson AJ: Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr 1992;121:49–55.
9.
Takano K, Shizume, Hibi I, and the Committee for the Treatment of Turner Syndrome: Long-term effects of growth hormone treatment on height in turner syndrome: Results of a 6-year multicentre study in Japan. Horm Res 1995;43:141–143.
10.
Pasquino AM, Passeri F, Municchi G, Segni M, Pucarelli I, Larizza D, Bossi G, Severi F, Galasso C: Final height in Turner syndrome patients treated with growth hormone. Horm Res 1996;46:269–272.
11.
Stahnke N, Attanasio A, Van den Broeck J, Partsch CJ, Zeisel HJ: GH treatment studies to final height in girls with Turner syndrome: The German experience; in Albertsson-Wikland K, Ranke M (eds): Turner Syndrome in a Life Span Perspective: Research and Clinical Aspects. Amsterdam, Elsevier, 1995, pp 95–103.
12.
Massa G, Otten BJ, De Muinck Keizer-Schrama S, Delemarre-van de Waal HA, Jansen M, Vulsma T, Oostdijk W, Waelkens JJ, Wit JM: Treatment with two growth hormone regimens in girls with Turner syndrome: Final height results. Horm Res 1995;42:144–146.
13.
Van-den-Broeck J, Massa GC, Attanasio A, Matranga A, Chaussain JL, Price DA, Aarskog D, Wit JM: Final height after long term growth hormone treatment in Turner syndrome. J Pediatr 1995;127:729–735.
14.
Rochiccioli R, Battin J, Bertrand AM, Bost M, Cabrol S, Le Bouc Y, Chaussain JL, Chatelain P, Colle M, Czernichow P, David M, Job JC, Lecornu M, Leheup B, Pierson M, Limal JM, Mariani R, Ponte C, Rappaport R, Tauber M: Final height in Turner syndrome patients treated with growth hormone. Horm Res 1995;44:172–176.
15.
Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustaffson J, Hagenäs L, Häger A, Ivarsson S, Karlberg J, Kriström B, Marcus C: Improved final height in girls with Turner’s syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 1996;81:635–640.
16.
Ranke MB, Price DA, Maes M, Albertsson-Wikland K, Lindberg A: Factors influencing final height in Turner syndrome following GH treatment: Results of the Kabi International Growth Study (KIGS); in Albertsson-Wikland K, Ranke M (eds): Turner Syndrome in a Life Span Perspective: Research and Clinical Aspects. Amsterdam, Elsevier, 1995, pp 161–165.
17.
Haeusler G, Schmitt K, Blümel P, Plöchl E, Waldhör T, Frisch H: Growth hormone doses in combination with oxandrolone in patients with Turner syndrome: Effect on bone maturation and final height. Acta Pediatr 1995;85:1408–1414.
18.
Chaussain JL, Gendre C, Job B, Ducret JP: Optimization of the dose of growth hormone in girls with Turner syndrome; in Hibi I, Takano K (eds): Basic and Clinical Aproach to Turner Syndrome. Amsterdam, Elsevier, 1993, pp 273–278.
19.
Van Teunenbroek A, De Muinck Keizer-Schrama S, Stijnen T, Jansen M, Otten BJ, Delemarre-Van de Waal H, Vulsma T, Wit MJ, Rouwe CW, Gosen J, Rongen-Westerlaken C, Drop S: Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. J Clin Endocrinol Metab 1996;81:4013–4021.
20.
Carel JC, Mathivon L, Gendrel C, Chaussain JL: Near normalization of final height with optimized usage of growth hormone in Turner syndrome (abstract). Horm Res 1997;48(suppl 2):4.
21.
Rochiccioli P, Dawid M, Malpuech G, Colle M, Limal JM, Battin J, Mariani R, Sultan C, Nivelon JL, Simonin G, Bost M, Chatelain P, Bertrand AM, Freycon R, Bouquier JJ, Pierron P: Study of final height in Turner’s syndrome: Ethnic and genetic influences. Acta Paediatr 1995;83:305–308.
22.
Lyon AJ, Preece MA, Grant DB: Growth curve for girls with Turner syndrome. Arch Dis Child 1995;60:932–935.
23.
Ranke MB, Pflüger H, Rosendahl W, Stubbe P, Enders H, Bierich JR, Majewski F: Turner syndrome: Spontaneous growth in 150 cases and review of the literature. Acta Paediatr Scand 1995;141:81–88.
24.
Haeusler G, Frisch H: Methods for evaluation of growth in Turner syndrome: Critical approach and review of the literature. Acta Paediatr Scand 1994;83:309–314.
25.
Haeusler G, Schemper M, Frisch H, Blümel P, Schmitt K, Plöchl E: Spontaneous growth in Turner syndrome: Evidence for a minor pubertal growth spurt. Eur J Pediatr 1992;151:283–287.
26.
Rongen-Westerlaken C, Wit JM, De Muinck Keizer-Schrama SMPF, Otten BJ, Oostdijk W, Delemarre-van der Waal HA, Gons MH, Bot A, Van den Brande JL: Growth hormone treatment in Turner syndrome accelerates growth and skeletal maturation. Eur J Pediatr 1992;151:477–481.
27.
Rudmann D, Moffitt SD, Fernhoff PM, McKenzie WJ, Kenny JM, Bain RP: The relation between growth velocity and serum somatomedin-C concentration. J Clin Endocrinol Metab 1981;52:622–627.
28.
Haeusler G, Schmitt K, Frisch H, Blümel P, Plöchl E, Waldhör T, Zachmann M: Treatment of patients with Ullrich Turner syndrome with conventional growth hormone doses and the combination with oxandrolone or testosterone: Effect on growth, IGF-I and IGFBP-3 concentrations. Eur J Pediatr 1995;154:437–444.
29.
Haeusler G, Schmitt K, Frisch H, Blümel P, Plöchl E, Waldhör T: Insulin, IGF binding protein 1 and sex hormone binding globulin in patients with Turner syndrome: Course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone. J Clin Endocrinol Metab 1996;81:536–541.
30.
Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz RL, and the Genentech Turner’s Collaborative Group: Carbohydrate and lipid metabolism in Turner syndrome: Effect of therapy with growth hormone, oxandrolone, and a combination of both. J Pediatr 1988;112:210–217.
31.
Haeusler G, Frisch H: Growth hormone in Turner syndrome: Short term and long term effects on metabolic parameters. Clin Endocrinol 1992;38:247–254.
32.
Weise M, James D, Hartmann KH, Reinhardt D, Leitner Ch, Böhles HJ, Attanasio A: Dose-dependent effect of growth hormone therapy on glucose metabolism in subjects with Turner syndrome. Horm Res 1993;39(suppl 2):25–29.
33.
Hoffman R: Insulin antagonistic effects of growth hormone in short children. Horm Res 1995;44:197–202.
34.
Saenger P, Wesoly S, Glickstein J, Appel P, Issenberg H: No evidence for ventricular hypertrophy in Turner syndrome after growth hormone therapy; in Albertsson-Wikland K, Ranke M (eds): Turner Syndrome in a Life Span Perspective: Research and Clinical Aspects. Amsterdam, Elsevier, 1995, pp 259–266.
35.
Heuschmann D, Butenandt O, Vogel M: Left ventricular volume and mass in children on growth hormone therapy compared with untreated children. Eur J Pediatr 1996;155:77–80.
36.
Blethen SS, Rundle CA: Slipped capital femoral epiphysis in children treated with growth hormone. Horm Res 1996;46:113–116.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.